| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.0M | — | +46.1% |
| R&D Expense | $3.9M | — | +69.0% |
| SG&A Expense | $10.0M | — | +12.9% |
| Operating Income | -$9.7M | — | -19.5% |
| Net Income | -$9.7M | — | +0.6% |
| EPS (Basic) | -$0.45 | — | -350.0% |
| EPS (Diluted) | -$0.45 | — | -350.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $20.6M | -31.7% | -30.4% |
| Accounts Receivable | $7.7M | +46.8% | +37.8% |
| Inventory | $2.0M | -11.7% | -19.7% |
| Current Assets | $34.1M | -19.8% | -13.5% |
| Total Assets | $38.8M | -17.7% | -8.0% |
| Current Liabilities | $16.2M | -1.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.2M | — | +27.7% |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | -$120K | — | +97.0% |
| -44.8% |
| Total Liabilities | $22.7M | +1.5% | -62.6% |
| Stockholders' Equity | $16.1M | -35.1% | +186.4% |